ReproNovo
- Headquarters
- Lausanne
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Website
- repronovo.com
- Total Funding
- $62.0M
- Last Round
- $62.0M Series AMay 2025
About
ReproNovo is a biopharmaceutical company developing innovative therapeutic solutions for reproductive medicine and women's health, including male and female infertility and uterine conditions like adenomyosis. Founded in 2021 and headquartered in Lausanne, Switzerland, the company has two Phase 2 clinical-stage assets: RPN-001 (leflutrozole) for male infertility and RPN-002 (nolasiban) for adenomyosis management and improved IVF outcomes.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account